Cytodyn Inc (CYDY)

[justdafactss]

Week #8- No unblinding, s/p couldnt close in the 5's.

Doubtful a govt will want to do business with a co that releases lame excuses like this (with no 8K filing of this press release)---

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are eager to reach conclusion in our discussions with all the regulatory agencies for the path going forward and will release the details of our data and the results of our discussions with regulatory agencies in the coming weeks.” Details of the Company’s ongoing discussions with the regulatory agencies are confidential.
https://www.globenewswire.com/news-release/2021/02/22/2179338/0/en/CytoDyn-in-Discussions-with-U-S-FDA-MHRA-and-Health-Canada-After-Unblinding-its-CD12-Trial-Data-for-Severe-to-Critically-Ill-COVID-19-Patients.html

And "inventory" consisting of "raw materials"---

Note 3. Inventories
The Company’s inventory as of November 30, 2020 and May 31, 2020 was $99.1 million and $19.1 million, respectively. Inventory as of November 30, 2020 consisted of raw materials purchased for future commercial production and work-in-progress inventory related to the substantially completed commercial production of pre-launch inventories of leronlimab to support the Company’s expected approval of the product as a combination therapy for HIV patients in the United States. Work-in-progress consists of bulk drug substance, which is the manufactured drug stored in bulk storage, and drug product, which is the manufactured drug in unlabeled vials. Bulk drug substance and drug product comprised approximately $41.1 million and $29.7 million, respectively, of work-in-progress inventory.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1175680/000119312521004744/d17792d10q.htm